Cover Image

Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors

Objective: chronic myeloid leukemia (CML) is a myeloproliferative confusion characterized by the occurrence of an acquired mutation which affect the hematopoietic stem cell, treatment of CML with tyrosine kinase inhibitors (TKI) has resulted in high response rates compared to the interferon alpha an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bassam Francis Matti (Author), Shahla'a Fadhil Sabir (Author), Maysaa Ali Abdul Khaleq (Author), Marwah Hasan Al kaabi (Author)
Format:	Book
Published:	College of Pharmacy / Mustansiriyah University, 2018-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia
by: Luma Al-Ali, et al.
Published: (2024)

Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
by: Smeeta GAJENDRA, et al.
Published: (2019)

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
by: Marta Romo-González, et al.
Published: (2020)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
by: El Rassi F, et al.
Published: (2013)

An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
by: Tiziana Grafone, et al.
Published: (2012)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Olga Mulas, et al.
Published: (2021)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
by: Noor E. Verhagen, et al.
Published: (2023)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
by: Raquel Vinhas, et al.
Published: (2017)

Use of tyrosine kinase inhibitor by patients with chronic myeloid leukemia at a public hematology institution in the state of Amazonas, Brazil
by: Andreia D. MENEZES, et al.
Published: (2020)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
by: Yeojae Kim, et al.
Published: (2022)

Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report
by: Michelle Hyunju Lee, et al.
Published: (2024)

Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors
by: Alessandro Allegra, et al.
Published: (2024)

Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria
by: Veselina Goranova-Marinova, et al.
Published: (2023)

Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria
by: Veselina Goranova-Marinova, et al.
Published: (2024)

Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
by: Wulyo Rajabto, et al.
Published: (2022)

In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study
by: Raluca-Andrada Munteanu, et al.
Published: (2024)

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
by: Peter Batar, et al.
Published: (2024)

COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
by: Tutik Harjianti, et al.
Published: (2023)

Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
by: Peter Batar, et al.
Published: (2024)

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells
by: Yuelong Jiang, et al.
Published: (2022)

CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
by: Lorena Vigón, et al.
Published: (2019)

COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
by: R. I. Yagudina, et al.
Published: (2015)

COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
by: R. I. Yagudina, et al.
Published: (2015)

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later
by: Max Robles-Nasta, et al.
Published: (2024)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
by: Meike Kaehler, et al.
Published: (2021)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011)

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study
by: Hélène Haguet, et al.
Published: (2020)

Tyrosine kinases in rheumatoid arthritis
by: Kobayashi Akiko, et al.
Published: (2011)

Myeloid Leukemia
Published: (2018)

Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
by: Ruixin Gu, et al.
Published: (2022)

Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Megumi Kikuya, et al.
Published: (2021)

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease
by: Mirella Pastore, et al.
Published: (2019)

Tyrosine Kinases as Druggable Targets in Cancer
Published: (2019)

Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation
by: Huang R, et al.
Published: (2023)

Myeloid Leukemia Clinical Diagnosis and Treatment
Published: (2012)

Myeloid Leukemia Basic Mechanisms of Leukemogenesis
Published: (2011)

14 Treatment with tyrosine kinase inhibitors make PBMCs from patients with chronic myeloid leukemia less susceptible to HIV-1 infection: control of CD4+ T cell activation to control HIV-1 replication
by: Mercedes Bermejo, et al.
Published: (2017)

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond
by: Yu Zhou, et al.
Published: (2024)

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia
by: Erica Rodrigues de Araujo Vasconcelos, et al.
Published: (2017)